Sodium hydride → Ethyl 3-(5-phenoxymethyl-2-oxooxazolidin-3-yl)propionate
反応式
[H-].[Na+].[O:3]([CH2:10][CH:11]1[O:15][C:14](=[O:16])[NH:13][CH2:12]1)[C:4]1[CH:9]=[CH:8][CH:7]=[CH:6][CH:5]=1.Br[CH2:18][CH2:19][C:20]([O:22][CH2:23][CH3:24])=[O:21]>CN(C)C=O>[O:3]([CH2:10][CH:11]1[O:15][C:14](=[O:16])[N:13]([CH2:18][CH2:19][C:20]([O:22][CH2:23][CH3:24])=[O:21])[CH2:12]1)[C:4]1[CH:9]=[CH:8][CH:7]=[CH:6][CH:5]=1参加物
5
実験手順
A procedure similar to that described in Preparation 4 was repeated, except that 113 mg of sodium hydride (as a 55% by weight dispersion in mineral oil), 10 ml of anhydrous dimethylformamide, 420 mg of 5-phenoxymethyloxazolidin-2-one (prepared as described in Preparation 112) and 471 mg of ethyl 3-bromopropionate were used, to give 463 mg of the title compound having an Rf value of 0.34 (on silica gel thin layer chromatography, using a 2:1 by volume mixture of ethyl acetate and hexane as the developing solvent).
後処理
- customA procedure similar to that described in Preparation 4
出典と根拠
- ORDレコード
- ord-2e3a43e5c6694be2b6f077fa43165ac2
- 出典データセット
- uspto-grants-1996_11
- 特許番号
- US05578620
反応ノート
読み込み中…